

[Home](#) > [About Us](#) > [Cancer.Net Editorial Board](#) > [Specialty Editors](#) > Jaffer Ajani, MD

Printed February 1, 2015 from <http://www.cancer.net/about-us/cancernet-editorial-board/specialty-editors/jaffer-ajani-md>

---

## **Jaffer Ajani, MD** [1]



### **Cancer.Net Specialty Editor: Endocrine Tumors**

MD Anderson Cancer Center, Houston, TX

Dr. Jaffer A. Ajani, is a Professor of Cancer Medicine at the MD Anderson Cancer Center at The University of Texas in Houston, Texas.

Dr. Ajani earned his medical degree at Government Medical College in Nagpur, India and completed a residency program in general surgery and orthopedics at the Government Medical College. After completing two more residency programs in family practice and internal medicine at Altoona General Hospital, Pennsylvania State University, Altoona, Pennsylvania, and Tulane University School of Medicine, New Orleans, Louisiana, respectively, Dr. Ajani was awarded a fellowship in medical oncology at The University of Texas MD Anderson Cancer Center in Houston.

Certified in Medical Oncology by the American Board of Internal Medicine, Ajani has authored over 380 peer-reviewed articles and was cited in *Good Housekeeping Magazine* as being among the Best Doctors in America for Colorectal Cancer.

Disclosure: In the past two years, Dr. Ajani has served as a consultant/advisor for Sanofi, Merck, NCCN, Novartis, Bristol-Myers Squibb, Abraxis BioScience, ACT Biotech, Bayer, ImClone Systems, Onmark, Inc., Lilly, IMER, Drais Pharmaceuticals, Roche/Genentech, Novocure, and Thrombosis Research Institute; and received research funding from Taiho Pharmaceutical, Adherex Technologies, NS Pharma, Sanofi, IPCT/CRF, ImClone Systems, Novartis, Mebiopharm, Ascenta Therapeutics, ACT Biotech, Genta, and Bristol-Myers Squibb.

Last Updated: May 24, 2012

---

#### **Links:**

[1] <http://www.cancer.net/about-us/cancernet-editorial-board/specialty-editors/jaffer-ajani-md>